sr141716 has been researched along with ketamine in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR | 1 |
| Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR | 1 |
| Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR | 1 |
| France, CP; McMahon, LR | 1 |
| McMahon, LR | 1 |
| Fang, Q; Li, D; Li, F; Liu, Y; Lu, L; Wang, J; Zhao, M | 1 |
| Burgos, E; Goicoechea, C; Martín, MI; Pascual, D | 1 |
| Chong, HJ; Haussleiter, IS; Juckel, G; Kawohl, W; Maier, C; Norra, C; Roser, P | 1 |
| Butler, P; Munafò, MR; Nutt, DJ; Robinson, ES; Stuart, SA | 1 |
1 trial(s) available for sr141716 and ketamine
| Article | Year |
|---|---|
Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Evoked Potentials, Auditory; Excitatory Amino Acid Antagonists; Humans; Ketamine; Male; Piperidines; Prospective Studies; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, N-Methyl-D-Aspartate; Rimonabant; Schizophrenia; Young Adult | 2011 |
10 other study(ies) available for sr141716 and ketamine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Highly predictive and interpretable models for PAMPA permeability.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Humans; Models, Biological; Organic Chemicals; Regression Analysis; Support Vector Machine | 2017 |
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility | 2019 |
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States | 2020 |
Discriminative stimulus effects of the cannabinoid antagonist, SR 141716A, in delta -sup-9-tetrahydrocannabinol-treated rhesus monkeys.
Topics: Anesthetics; Animals; Behavior, Animal; Cannabinoids; Cocaine; Discrimination Learning; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Female; Ketamine; Macaca mulatta; Male; Photic Stimulation; Piperidines; Psychotropic Drugs; Pyrazoles; Rimonabant; Substance Withdrawal Syndrome | 2003 |
Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
Topics: Animals; Benzoxazines; Cannabinoids; Conditioning, Operant; Cyclohexanols; Discrimination Learning; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Female; Hallucinogens; Humans; Injections, Intravenous; Injections, Subcutaneous; Ketamine; Macaca mulatta; Male; Midazolam; Morpholines; Naphthalenes; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors | 2006 |
Cannabinoid CB(1) receptor antagonist rimonabant attenuates reinstatement of ketamine conditioned place preference in rats.
Topics: Animals; Behavior, Animal; Conditioning, Psychological; Disease Models, Animal; Dose-Response Relationship, Drug; Extinction, Psychological; Injections, Intraperitoneal; Ketamine; Male; Piperidines; Psychotropic Drugs; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Recurrence; Rimonabant; Substance-Related Disorders | 2008 |
Antinociceptive effect of the cannabinoid agonist, WIN 55,212-2, in the orofacial and temporomandibular formalin tests.
Topics: Analgesics; Analgesics, Opioid; Anesthetics, Dissociative; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Benzoxazines; Camphanes; Facial Pain; Formaldehyde; Indomethacin; Inflammation; Ketamine; Male; Morphine; Morpholines; Motor Activity; Naphthalenes; Pain; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Temporomandibular Joint Disorders | 2010 |
Distinct Neuropsychological Mechanisms May Explain Delayed- Versus Rapid-Onset Antidepressant Efficacy.
Topics: Animals; Antidepressive Agents; Association Learning; Brain; Cannabinoid Receptor Antagonists; Carbolines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; GABA Antagonists; Ketamine; Male; Mood Disorders; Piperidines; Pyrazoles; Rats; Reaction Time; Reinforcement, Psychology; Rimonabant; Stress, Psychological; Venlafaxine Hydrochloride | 2015 |